DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

Seymour said the Government had, in 2024, allocated Pharmac its largest-ever budget of $6.294 billion over four years, plus a ...

The French river cruise prize package is sold for $29,000 to top bidder Dennis Walsh and Cathie Waites at Rotorua's Supper Club charity fundraiser. Police, Rotorua's council and protesters discuss ...

Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined IQVIA to conduct the bioequivalence study or present safety data for ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...

COPENHAGEN, Denmark I March 10, 2025 I Genmab A/S (Nasdaq: GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term outcomes thwarted by repeated cycles of relapse and remission. This is ...

Its presence highlights immunophenotyping’s role in T-LGLL diagnosis. Recent findings show the upregulation of cell adhesion-related genes on CD34 + cells after daratumumab-based therapy, suggesting ...